The country of origin of Metronidazole Tablets, USP in dosage form
No revocation or modification of this ruling appears in the Customs Bulletin issues read here (Nov 6, 2024 through Nov 18, 2026), where CBP publishes most such actions. That is not confirmation that the ruling is still in effect. Confirm its status with CBP before relying on it (ruling on CBP CROSS).
Key passages, quoted from the ruling
- Therefore, we find the country of origin of the Metronidazole Tablets in dosage form will be India, where the API is made.
Ruling text
In your letter dated September 23, 2025, you requested a country of origin ruling on Metronidazole Tablets. Metronidazole, imported in 250 mg and 500 mg tablets, is a medicinal preparation containing Metronidazole, a synthetic nitroimidazole antimicrobial agent, as the active ingredient. It is indicated for the prevention and treatment of certain bacterial and protozoal infections.
You stated that the active pharmaceutical ingredient (API), Metronidazole, is manufactured in India and that the finished tablets in dosage form are also made in India. In India, Metronidazole will be mixed with various inactive ingredients to produce the final Metronidazole Tablets in dosage form. When determining the country of origin, the substantial transformation analysis is applicable. See, e.g., Headquarters Ruling Letter (“HQ”) H301619, dated November 6, 2018.
The test for determining whether a substantial transformation will occur is whether an article emerges from a process with a new name, character, or use different from that possessed by the article prior to processing. See Texas Instruments Inc. v. United States, 681 F.2d 778 (C.C.P.A. 1982). This determination is based on the totality of the evidence. See National Hand Tool Corp. v. United States, 16 C.I.T. 308 (1992), aff’d, 989 F.2d 1201 (Fed. Cir. 1993).
In this case, the active ingredient Metronidazole is made in India and the mixing of the API with the inactive ingredients into the final tablets is also made in India. Therefore, we find the country of origin of the Metronidazole Tablets in dosage form will be India, where the API is made.
This merchandise may be subject to the Federal Food, Drug, and Cosmetic Act and/or The Public Health Security and Bioterrorism Preparedness and Response Act of 2002 (The Bioterrorism Act), which are administered by the U.S. Food and Drug Administration (FDA). Information on the Federal Food, Drug, and Cosmetic Act, as well as The Bioterrorism Act, can be obtained by calling the FDA at 1-888-463-6332, or by visiting their website at www.fda.gov.
The text above is an excerpt. The official ruling, with its letterhead, signature and any attachments, is on CBP CROSS (N354139).